Vaccination against tuberculosis: Current status and future promise

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 3, 2004, Pages 345-352

  Kaufmann, Stefan H E ^a   Mittrücker, Hans Willi ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Attenuation; BCG; Correlate of protection; Granuloma; T lymphocyte; Tuberculosis; Vaccination

Indexed keywords

ANTIGEN; BCG VACCINE; DNA VACCINE; MYCOBACTERIUM VACCINE; SUBUNIT VACCINE; VACCINE;

BCG VACCINATION; DRUG DESIGN; DRUG EFFICACY; GRANULOMA; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TUBERCULOSIS; TUBERCULOSIS CONTROL; VACCINATION;

EID: 3042775425     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829506     Document Type: Review

References (48)

1. Collins HL, Kaufmann SHE. Prospects for better tubercolosis vaccines. Lancet Infect Dis 2001;1:21-28
2. Kaufmann SHE. How can immunology contribute to the control of tubercolosis? Nat Rev Immunol 2001;1:20-30
3. Fine PEM. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989;11:S353-S359
4. Kaufmann SHE. Is the development of a new tuberculosis vaccine possible? Nat Med 2000;6:955-960
5. Casadevall A, Pirofski LA. Exploiting the redundancy in the immune system: vaccines can mediate protection by eliciting "unnatural" immunity. J Exp Med 2003;197:1401-1404
6. Van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-1179
7. Casanova J-L, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002;20:581-620
8. Clements CJ. Vaccination: the current status of BCG. In: Kaufmann SHE, Hahn H, eds. Mycobacteria and TB. Basel: Karger; 2003:46-66
9. Reiter H. Die Säuglingstuberkulose in Lübeck. Berlin: Julius Springer; 1935
10. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702
11. Stanford JL, Shield MJ, Rook GAW. How environmental mycobacteria may pre-determine the protective efficacy of BCG. Tubercle 1981;62:55-62
12. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Resp Dis 1966;94:553
13. Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002;70:672-678
14. Schaible UE, Collins HL, Kaufmann SHE. Confrontation between intracellular bacteria and the immune system. Adv Immunol 1999;71:267-377
15. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216
16. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-736
17. Kaufmann SHE. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann Rheum Dis 2002;61:54-58
18. Geijtenbeek TBH, van Vliet SJ, Koppel EA, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2002;197:7-17
19. Tailleux L, Schwartz O, Herrmann JL, et al. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med 2002;197:121-127
20. Kaufmann SHE, Schaible UE. A dangerous liaison between the two major killers: M. tuberculosis and HIV target in dendritic cells through DC-SIGN. J Exp Med 2003;197:1-5
21. Raupach B, Kaufmann SHE. Immune response to intracellular bacteria. Curr Opin Immunol 2001;13:417-428
22. Schaible UE, Winau F, Sieling PA, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003;9:1039-1046
23. + T-cells of mycobacteria growing in human macrophages. Science 1993;260:984-986
24. Kaufmann SHE. Gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA 1996;93:2272-2279
25. Schaible UE, Kaufmann SHE. CD1 and CD1-restricted T cells in infections with intracellular bacteria. Trends Microbiol 2000;8:419-425
26. γ2 T cells during mycobacterial infections. Science 2002;295:2255-2258
27. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000;68:791-795
28. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000;97:13853-13858
29. Olsen AW, van Pinxteren LAH, Okkels LM, Rasmussen PB, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect Immun 2001;69:2773-2778
30. Jungblut PR, Schaible UE, Mollenkopf HJ, et al. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol 1999;33:1103-1117
31. Domenech P, Barry CE, Cole ST. Mycobacterium tuberculosis in the postgenomic age. Curr Opin Microbiol 2001;4:28-34
32. Skeiky YAW, Ovendale PJ, Jen S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control infection. J Immunol 2000;165:7140-7149
33. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med 1996;2:888-892
34. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2:893-898
35. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284:1520-1523
36. Berthet FX, Lagranderie M, Gounon P, et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 1998;282:759-762
37. Yuan Y, Crane DD, Simpson RM, et al. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci USA 1998;95:9578-9583
38. McKinney JD, zu Bentrup KH, Munoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-738
39. Cox JS, Chen B, McNeil M, Jacobs WR. Complex lipid determine tissue specific replication of Mycobacterium tuberculosis in mice. Nature 1999;402:79-83
40. Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR, Bloom BR. Auxotrophic vaccines for tuberculosis. Nat Med 1996;2:334-337
41. Smith DA, Parish T, Stoker NG, Bancroft GJ. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001;69:1142-1150
42. Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9:533-539
43. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SHE. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 1998;95:5299-5304
44. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 1996;93:934-939
45. Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C. Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 2002;70:6549-6557
46. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001;69:681-686
47. Feng CG, Palendira U, Demangel C, Spratt JM, Malin AS, Britton WJ. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis. Infect Immun 2001;69:4174-4176
48. Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM. Boosting vaccine for tuberculosis. Infect Immun 2001;69:2714-2717